GlobeNewswire: Geron Corporation Contains the last 10 of 108 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:12:49ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/11/05/2121534/0/en/Geron-Corporation-Reports-Third-Quarter-2020-Financial-Results-and-Current-Events.html?f=22&fvtc=4&fvtv=25513Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events2020-11-05T21:05:00Z<![CDATA[FOSTER CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020. The Company will host a conference call today at 4:30 p.m. ET to discuss third quarter financial results and current events. As of September 30, 2020, Geron had approximately $274 million in cash and investments. Based on current planning assumptions, the Company estimates its current financial resources to be sufficient for its operations until the end of 2022.]]>https://www.globenewswire.com/news-release/2020/07/01/2056233/0/en/Geron-Receives-Positive-Opinion-from-the-EMA-Committee-for-Orphan-Medicinal-Products-for-Orphan-Drug-Designation-in-the-European-Union-for-Imetelstat-to-Treat-Myelodysplastic-Syndr.html?f=22&fvtc=4&fvtv=25513Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes2020-07-01T12:30:00Z<![CDATA[MENLO PARK, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the Company’s application for orphan drug designation of its first-in-class telomerase inhibitor, imetelstat, as a potential treatment for myelodysplastic syndromes (MDS). The Company expects that the European Commission, based on this positive opinion of the COMP, will formally grant the orphan drug designation for the European Union (EU) by the end of July. Imetelstat has already been granted orphan drug designation by the United States Food and Drug Administration as a potential treatment for MDS.]]>https://www.globenewswire.com/news-release/2020/06/12/2047437/0/en/Geron-Reports-Four-Imetelstat-Data-Presentations-at-Virtual-Edition-of-the-European-Hematology-Association-EHA-Annual-Congress.html?f=22&fvtc=4&fvtv=25513Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress2020-06-12T12:30:00Z<![CDATA[MENLO PARK, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an oral presentation and three poster presentations of new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, are now available on Geron’s website as well as to participants of the Virtual Edition of the 25th Annual EHA Annual Congress.]]>https://www.globenewswire.com/news-release/2020/05/28/2040550/0/en/Geron-Corporation-Reports-First-Quarter-2020-Financial-Results.html?f=22&fvtc=4&fvtv=25513Geron Corporation Reports First Quarter 2020 Financial Results2020-05-28T20:05:00Z<![CDATA[MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a conference call today at 4:30 p.m. ET to discuss the recently announced planned Phase 3 clinical trial in refractory MF, as well as an update on the ongoing IMerge Phase 3 clinical trial in lower risk MDS and first quarter financial results.]]>https://www.globenewswire.com/news-release/2020/05/27/2039761/0/en/Geron-Corporation-Announces-the-Closing-of-its-Public-Offering-of-Common-Stock-and-Warrants.html?f=22&fvtc=4&fvtv=25513Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants2020-05-27T20:30:00Z<![CDATA[MENLO PARK, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 107,049,375 shares of its common stock and pre-funded warrants to purchase 8,335,239 shares of common stock, together with accompanying warrants to purchase 57,692,307 shares of common stock. The common stock and pre-funded warrants were sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The combined offering price to the public of each share of common stock and accompanying warrant was $1.30. The combined offering price to the public of each pre-funded warrant and accompanying warrant was $1.299.]]>https://www.globenewswire.com/news-release/2020/05/22/2037525/0/en/Geron-Corporation-Announces-the-Pricing-of-its-Public-Offering-of-Common-Stock-and-Warrants.html?f=22&fvtc=4&fvtv=25513Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants2020-05-22T11:15:00Z<![CDATA[MENLO PARK, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 107,049,375 shares of its common stock and pre-funded warrants to purchase 8,335,239 shares of common stock, together with accompanying warrants to purchase 57,692,307 shares of common stock. The common stock and pre-funded warrants will be sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The combined offering price to the public of each share of common stock and accompanying warrant is $1.30. The combined offering price to the public of each pre-funded warrant and accompanying warrant is $1.299.]]>https://www.globenewswire.com/news-release/2020/05/21/2037263/0/en/Geron-Corporation-Announces-Proposed-Public-Offering-of-Common-Stock-and-Warrants.html?f=22&fvtc=4&fvtv=25513Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants2020-05-21T20:03:00Z<![CDATA[MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2020/05/21/2037258/0/en/Geron-Announces-Plans-for-Imetelstat-Phase-3-Clinical-Trial-in-Myelofibrosis-and-Other-Updates.html?f=22&fvtc=4&fvtv=25513Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates2020-05-21T20:01:00Z<![CDATA[MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced plans for a Phase 3 clinical trial in MF patients who are refractory to treatment with a janus kinase (JAK) inhibitor, including trial design and expected timelines for trial start and future data readouts. Geron also provided an update on its ongoing IMerge Phase 3 clinical trial in lower risk MDS and reported revised fiscal year 2020 operating expense guidance.]]>https://www.globenewswire.com/news-release/2020/04/08/2013917/0/en/Geron-to-Present-at-Needham-Virtual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=25513Geron to Present at Needham Virtual Healthcare Conference2020-04-08T20:30:00Z<![CDATA[MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 19th Annual Needham Virtual Healthcare Conference at 10:00 a.m. ET on Wednesday, April 15, 2020.]]>https://www.globenewswire.com/news-release/2020/04/02/2010733/0/en/Geron-Provides-COVID-19-Related-Business-Update.html?f=22&fvtc=4&fvtv=25513Geron Provides COVID-19 Related Business Update2020-04-02T12:00:00Z<![CDATA[MENLO PARK, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical development biopharmaceutical company, today announced an update to information from its March 12 year-end conference call related to the impact of the COVID-19 pandemic on the Company’s business, and described the measures being taken to protect the safety of Geron’s employees and patients in its clinical trials.]]>